title: Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis.
abstract: Previous studies concerning the association between body mass index (BMI) and mortality in prostate cancer yielded mixed results. We investigated the association by performing a meta-analysis of all available studies.
  
  
  
  Relevant studies were identified by searching PubMed and EMBASE to August 2015. We calculated the summary hazard ratio (HR) and 95% confidence interval (CI) using random-effects models. We estimated combined HRs associated with defined increments of BMI, using random-effects meta-analysis and dose-response meta-regression models.
  
  
  
  Thirty-seven cohort studies and one case-control study involving 27 38 000 patients of prostate cancer were selected for meta-analysis. The summary results indicated higher prediagnosis BMI but not postdiagnosis BMI was associated with increased risk of death from prostate cancer. An increment of every 5 kg/m(2) in prediagnosis BMI was associated with a 15% higher prostate cancer-specific mortality (HR=1.15, 95% CI: 1.07-1.23, P<0.01). Prediagnosis or postdiagnosis BMI showed no effect on all-cause mortality in prostate cancer patients.
  
  
  
  In conclusion, higher prediagnosis BMI is associated with a higher risk of death from prostate cancer. Considering the significant heterogeneity among included studies, these findings require confirmation in future studies.
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China.
authors.forename: S
authors.initials: S
authors.lastname: Zhong
authors.affiliation: Institute of Laboratory Medicine, Jinling Hospital of Nanjing University, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Yan
authors.affiliation: Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Departments of Oncology, Xuzhou Medical College, Xuzhou, China.
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China.
authors.forename: J
authors.initials: J
authors.lastname: Tang
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhao
mesh_terms: D015992:Body Mass Index; D016022:Case-Control Studies; D002423:Cause of Death; D015331:Cohort Studies; D006801:Humans; D008297:Male; D009026:Mortality; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality; D017594:Publication Bias